Characteristics of 249 patients with stage IIIb AL amyloidosis
| Variables . | Overall population 249 patients N (%), mean (IQR) . |
|---|---|
| Age, years | 68 (60-74) |
| Sex, male | 145 (58) |
| Organ involvement (other than heart) | |
| Kidney | 129 (52) |
| Liver | 43 (17) |
| ST | 51 (20) |
| GI | 6 (2) |
| ANS | 21 (8) |
| PNS | 23 (9) |
| Number of involved organs | 2 (1-3) |
| Isolated heart involvement | 74 (30) |
| NYHA class | |
| I | 33 (13) |
| II | 64 (26) |
| III | 139 (56) |
| IV | 13 (5) |
| NT-proBNP, ng/L | 17089 (12179-25014) |
| Troponin I, ng/mL | 0.265 (0.169-0.500) |
| eGFR, mL/min × 1.73 m2 | 43 (27->60) |
| eGFR < 30 mL/min × 1.73 m2 | 76 (31) |
| Renal stage | |
| I | 108 (43) |
| II | 111 (45) |
| III | 26 (10) |
| Patients in dialysis at diagnosis | 2 (1) |
| dFLC, mg/L | 259 (142-543) |
| dFLC < 50 mg/L | 13 (5) |
| dFLC > 180 mg/L | 167 (67) |
| Involved/uninvolved FLC rate > 100 | 9 (4) |
| BMPC, % | 12 (8-20) |
| BMPC > 20% | 41 (16) |
| Treatment | |
| MDex | 98 (39) |
| CyBorD | 75 (30) |
| BMDex | 43 (18) |
| IMiDs | 28 (11) |
| rituximab | 5 (1) |
| Variables . | Overall population 249 patients N (%), mean (IQR) . |
|---|---|
| Age, years | 68 (60-74) |
| Sex, male | 145 (58) |
| Organ involvement (other than heart) | |
| Kidney | 129 (52) |
| Liver | 43 (17) |
| ST | 51 (20) |
| GI | 6 (2) |
| ANS | 21 (8) |
| PNS | 23 (9) |
| Number of involved organs | 2 (1-3) |
| Isolated heart involvement | 74 (30) |
| NYHA class | |
| I | 33 (13) |
| II | 64 (26) |
| III | 139 (56) |
| IV | 13 (5) |
| NT-proBNP, ng/L | 17089 (12179-25014) |
| Troponin I, ng/mL | 0.265 (0.169-0.500) |
| eGFR, mL/min × 1.73 m2 | 43 (27->60) |
| eGFR < 30 mL/min × 1.73 m2 | 76 (31) |
| Renal stage | |
| I | 108 (43) |
| II | 111 (45) |
| III | 26 (10) |
| Patients in dialysis at diagnosis | 2 (1) |
| dFLC, mg/L | 259 (142-543) |
| dFLC < 50 mg/L | 13 (5) |
| dFLC > 180 mg/L | 167 (67) |
| Involved/uninvolved FLC rate > 100 | 9 (4) |
| BMPC, % | 12 (8-20) |
| BMPC > 20% | 41 (16) |
| Treatment | |
| MDex | 98 (39) |
| CyBorD | 75 (30) |
| BMDex | 43 (18) |
| IMiDs | 28 (11) |
| rituximab | 5 (1) |
ANS, autonomic nervous system involvement; BMDex, bortezomib, melphalan, and dexamethasone; BMPC, bone marrow plasma cells; CyBorD, cyclophosphamide, bortezomib, and dexamethasone; FLC, free light chain; GI, gastrointestinal; IMiDs, immunomodulatory drugs; IQR, interquartile range; PNS, peripheral nervous system; ST, soft tissues.